115 related articles for article (PubMed ID: 17303606)
1. A randomised controlled trial of total immunosuppression withdrawal in stable liver transplant recipients.
Assy N; Adams PC; Myers P; Simon V; Ghent CN
Gut; 2007 Feb; 56(2):304-6. PubMed ID: 17303606
[No Abstract] [Full Text] [Related]
2. Randomized controlled trial of total immunosuppression withdrawal in liver transplant recipients: role of ursodeoxycholic acid.
Assy N; Adams PC; Myers P; Simon V; Minuk GY; Wall W; Ghent CN
Transplantation; 2007 Jun; 83(12):1571-6. PubMed ID: 17589339
[TBL] [Abstract][Full Text] [Related]
3. Does prophylactic ursodeoxycholic acid treatment of liver transplant patients prevent acute rejection?
Keiding S
Hepatology; 1998 Jun; 27(6):1748-9. PubMed ID: 9620354
[No Abstract] [Full Text] [Related]
4. A randomized clinical trial of ursodeoxycholic acid as adjuvant treatment to prevent liver transplant rejection.
Barnes D; Talenti D; Cammell G; Goormastic M; Farquhar L; Henderson M; Vogt D; Mayes J; Westveer MK; Carey W
Hepatology; 1997 Oct; 26(4):853-7. PubMed ID: 9328304
[TBL] [Abstract][Full Text] [Related]
5. Failure of ursodeoxycholic acid to prevent acute cellular rejection after liver transplantation.
Pageaux GP; Blanc P; Perrigault PF; Navarro F; Fabre JM; Souche B; Domergue J; Larrey D; Michel H
J Hepatol; 1995 Aug; 23(2):119-22. PubMed ID: 7499781
[TBL] [Abstract][Full Text] [Related]
6. A prospective, randomized, double-blind trial evaluating the efficacy of ursodeoxycholic acid in prevention of liver transplant rejection.
Fleckenstein JF; Paredes M; Thuluvath PJ
Liver Transpl Surg; 1998 Jul; 4(4):276-9. PubMed ID: 9649640
[TBL] [Abstract][Full Text] [Related]
7. Evidence that ursodeoxycholic acid prevents steroid-resistant rejection in adult liver transplantation.
Clavien PA; Sharara AI; Camargo CA; Harland RC; Fitz JG
Clin Transplant; 1996 Dec; 10(6 Pt 2):658-62. PubMed ID: 8996761
[TBL] [Abstract][Full Text] [Related]
8. Ursodeoxycholic acid after liver transplantation: does conjugation with taurine make the difference?
Beuers U
Ital J Gastroenterol Hepatol; 1999; 31(6):469-71. PubMed ID: 10575564
[No Abstract] [Full Text] [Related]
9. Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis.
Heathcote EJ; Stone J; Cauch-Dudek K; Poupon R; Chazouilleres O; Lindor KD; Petz J; Dickson ER; Poupon RE
Liver Transpl Surg; 1999 Jul; 5(4):269-74. PubMed ID: 10388499
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant treatment with ursodeoxycholic acid reduces acute rejection after liver transplantation.
Friman S; Persson H; Scherstén T; Svanvik J; Karlberg I
Transpl Int; 1992; 5 Suppl 1():S187-9. PubMed ID: 14621771
[TBL] [Abstract][Full Text] [Related]
11. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
[TBL] [Abstract][Full Text] [Related]
12. [Primary biliary cirrhosis].
Corpechot C
Gastroenterol Clin Biol; 2003 Mar; 27(3 Pt 1):320-4. PubMed ID: 12700520
[No Abstract] [Full Text] [Related]
13. Treatment with immunosuppressives in patients with primary biliary cirrhosis who fail to respond to ursodiol.
Kaplan MM; Poupon R
Hepatology; 2009 Aug; 50(2):652. PubMed ID: 19309721
[No Abstract] [Full Text] [Related]
14. Efficacy of ursodeoxycholic acid as an adjuvant treatment to prevent acute cellular rejection after liver transplantation: a meta-analysis of randomized controlled trials.
Deng YL; Xiong XZ; Cheng NS
Hepatobiliary Pancreat Dis Int; 2014 Oct; 13(5):464-73. PubMed ID: 25308356
[TBL] [Abstract][Full Text] [Related]
15. Outcomes after complete immunosuppression withdrawal in liver transplant recipients: rejection-free graft tolerance or late acute rejection?
Yoshida EM; Chung SW
Can J Gastroenterol; 1998 Sep; 12(6):387-9. PubMed ID: 9867428
[No Abstract] [Full Text] [Related]
16. Pretransplant ursodeoxycholic acid therapy and liver transplantation in patients with primary biliary cirrhosis: win, win, win?
Benner KG
Liver Transpl Surg; 1999 Jul; 5(4):334-7. PubMed ID: 10388507
[No Abstract] [Full Text] [Related]
17. The impact of early corticosteroid withdrawal on graft survival in liver transplant recipients.
Meadows HB; Taber DJ; Pilch NA; Tischer SM; Baliga PK; Chavin KD
Transplant Proc; 2012 Jun; 44(5):1323-8. PubMed ID: 22664009
[TBL] [Abstract][Full Text] [Related]
18. The Nordic multicenter double-blind randomized controlled trial of prophylactic ursodeoxycholic acid in liver transplant patients.
Keiding S; Høckerstedt K; Bjøro K; Bondesen S; Hjortrup A; Isoniemi H; Erichsen C; Söderdahl G; Ericzon BG
Transplantation; 1997 Jun; 63(11):1591-4. PubMed ID: 9197351
[TBL] [Abstract][Full Text] [Related]
19. Present state of immunosuppressive therapy in liver transplant recipients.
Wiesner RH; Fung JJ
Liver Transpl; 2011 Nov; 17 Suppl 3():S1-9. PubMed ID: 21850697
[TBL] [Abstract][Full Text] [Related]
20. Treatment of primary biliary cirrhosis: therapy with choleretic and immunosuppressive agents.
Silveira MG; Lindor KD
Clin Liver Dis; 2008 May; 12(2):425-43; x-xi. PubMed ID: 18456189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
